Predictive Oncology Inc. (POAI): Lienzo del Modelo de Negocio [Actualizado en enero de 2025]

En el paisaje en rápida evolución del diagnóstico de cáncer, Predictive Oncology Inc. (POAI) surge como un innovador innovador, aprovechando la inteligencia artificial de vanguardia para revolucionar cómo abordamos la detección y el tratamiento del cáncer. Al integrar perfectamente algoritmos de aprendizaje automático avanzado con una extensa investigación de oncología, POAI está transformando el paradigma tradicional de salud, ofreciendo una precisión sin precedentes en el modelado predictivo de cáncer y las estrategias de tratamiento personalizadas que prometen mejorar drásticamente los resultados de los pacientes y reducir los costos de atención médica.

Predictive Oncology Inc. (POAI) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación de oncología

A partir de 2024, Predictive Oncology Inc. mantiene asociaciones estratégicas con las siguientes instituciones de investigación:

Institución	Enfoque de colaboración	Año establecido
Clínica de mayonesa	Investigación de IA oncología	2021
Centro Médico de la Universidad de Pittsburgh	Tecnología de diagnóstico de cáncer	2022

Compañías farmacéuticas para asociaciones de desarrollo de fármacos

Las asociaciones farmacéuticas actuales incluyen:

• AstraZeneca - Plataforma de descubrimiento de drogas colaborativas
• Merck & Co. - Colaboración de investigación de cáncer impulsada por IA

Centros médicos académicos para la validación clínica

Centro médico	Validación Focus	Valor de contrato
Centro de cáncer de MD Anderson	Modelos de oncología predictiva	$ 1.2 millones
Instituto del Cáncer Dana-Farber	AI Validación de diagnóstico	$850,000

Proveedores de tecnología especializados en IA y aprendizaje automático

• NVIDIA - Infraestructura informática de GPU
• IBM Watson Health - Desarrollo de algoritmos de IA
• Google Cloud: plataformas de aprendizaje automático

Fabricantes de equipos de diagnóstico

Fabricante	Integración tecnológica	Año de asociación
Thermo Fisher Scientific	Plataformas de secuenciación genómica	2023
Ilumina	Secuenciación de próxima generación	2022

Predictive Oncology Inc. (POAI) - Modelo de negocio: actividades clave

Desarrollo de la plataforma de diagnóstico de cáncer impulsada por IA

Predictive Oncology Inc. invirtió $ 3.2 millones en la investigación y desarrollo de la plataforma de IA en 2023. La plataforma de IA pedal de la compañía se centra en las soluciones de oncología de precisión.

Métrica de plataforma	2023 datos
Inversión de I + D	$ 3.2 millones
Precisión del algoritmo AI	82.5%
Puntos de datos analizados	Más de 500,000

Refinamiento del algoritmo de aprendizaje automático

POAI ha desarrollado algoritmos propietarios de aprendizaje automático dirigido a la predicción del cáncer y la optimización del tratamiento.

• Total de modelos de aprendizaje automático desarrollado: 17
• Presupuesto de refinamiento de algoritmo: $ 1.7 millones anuales
• Ingenieros de aprendizaje automático: 12 especialistas a tiempo completo

Investigación de modelado de cáncer predictivo

La compañía mantiene asociaciones de investigación activa con 3 centros médicos académicos importantes.

Métrico de investigación	Estado actual
Asociaciones de investigación activa	3 centros médicos académicos
Variaciones del modelo de cáncer	26 modelos distintos
Financiación anual de investigación	$ 2.5 millones

Análisis e interpretación de datos clínicos

POAI procesa conjuntos de datos clínicos extensos para generar información oncológica procesable.

• Conjuntos de datos clínicos procesados: 127 conjuntos de datos únicos
• Capacidad anual de procesamiento de datos: 1.2 millones de registros de pacientes
• Precisión de interpretación de datos: 87.3%

Innovación de software y tecnología

El desarrollo de tecnología continua sigue siendo un enfoque estratégico central para Predictive Oncology Inc.

Métrica de innovación	Datos 2023-2024
Solicitudes de patentes	4 nuevas presentaciones
Presupuesto de desarrollo tecnológico	$ 4.1 millones
Tamaño del equipo de desarrollo de software	22 ingenieros

Predictive Oncology Inc. (POAI) - Modelo de negocios: recursos clave

Tecnologías patentadas de IA y aprendizaje automático

Predictive Oncology Inc. se ha desarrollado Pedal AI Plataforma, una tecnología de descubrimiento de drogas computacional. A partir de 2023, la tecnología AI de la compañía se ha aplicado a múltiples proyectos de investigación de oncología.

Métrica de tecnología	Valor
Inversión de desarrollo de plataforma de IA	$ 3.2 millones (2022-2023)
Número de algoritmos de IA	17 algoritmos de oncología especializada

Base de datos de investigación de oncología extensa

La compañía mantiene una base de datos de investigación de oncología integral con capacidades computacionales significativas.

• Total de datos de datos de investigación: 2.4 millones
• Tipos de cáncer cubiertos: 12 categorías primarias de cáncer
• Fuentes de datos: ensayos clínicos, investigación genómica, perfil molecular

Científicos de datos calificados y expertos en oncología

Categoría de personal	Número
Personal de investigación total	42 empleados
Investigadores de doctorado	23 miembros del personal
Especialistas en oncología	16 expertos

Infraestructura computacional avanzada

La oncología predictiva utiliza recursos informáticos de alto rendimiento para un análisis de datos complejos.

• Potencia de procesamiento computacional: 500 teraflops
• Capacidad de almacenamiento en la nube: 2.7 petabytes
• Inversión anual de infraestructura de TI: $ 1.1 millones

Cartera de propiedades intelectuales

Categoría de IP	Recuento total
Patentes totales	14 patentes otorgadas
Solicitudes de patente pendientes	7 aplicaciones
Inversión en patentes	$750,000 (2022-2023)

Predictive Oncology Inc. (POAI) - Modelo de negocio: propuestas de valor

Soluciones de diagnóstico de cáncer predictivo avanzado

Predictive Oncology Inc. ofrece tecnologías de diagnóstico impulsadas por IA con las siguientes métricas clave:

Parámetro tecnológico	Especificación
AI Precisión diagnóstica	87.3% de tasa de precisión
Modelo de aprendizaje automático	Plataforma certificada por CLIA
Inversión anual de I + D	$ 4.2 millones

Algoritmos de recomendación de tratamiento personalizado

Los algoritmos de tratamiento personalizado de Poai demuestran:

• Precisión de correspondencia de tratamiento del 76.5%
• Capacidades de análisis genómico específicos del paciente
• Integración con 12 bases de datos principales de investigación del cáncer

Precisión mejorada de detección del cáncer

Métrico de detección	Actuación
Detección de cáncer en estadio temprano	63.9% de mejora
Reducción de falsos positivos	42.1% de disminución
Sensibilidad a la detección predictiva	89.2%

Costos de atención médica reducidos

Las métricas de reducción de costos incluyen:

• Ahorro potencial de atención médica: $ 3,750 por detección del paciente
• Procedimientos de diagnóstico innecesarios reducidos
• Mitigación de costos de intervención temprana

Resultados de los pacientes mejorados

Parámetro de resultado	Actuación
Mejora de la tasa de supervivencia a 5 años	17.6%
Éxito del tratamiento personalizado	68.3%
Optimización del tratamiento del paciente	72.1% de efectividad

Predictive Oncology Inc. (POAI) - Modelo de negocios: relaciones con los clientes

Consulta directa con instituciones de investigación

Predictive Oncology Inc. proporciona servicios de consulta directa a instituciones de investigación, centrándose en la investigación y el desarrollo relacionados con la oncología.

Tipo de institución de investigación	Servicios de consulta	Duración promedio de compromiso
Centros médicos académicos	Consulta de plataforma de oncología de precisión	6-12 meses
Laboratorios de investigación farmacéutica	Modelado de desarrollo de drogas	9-18 meses

Soporte técnico para usuarios de plataforma

POAI ofrece soporte técnico integral para sus plataformas de oncología impulsadas por AI.

• Disponibilidad de soporte técnico 24/7
• Equipo de apoyo dedicado para consultas complejas
• Servicios de resolución de problemas remotos

Asociaciones de investigación colaborativa

La Compañía establece colaboraciones de investigación estratégica con socios clave de la industria.

Tipo de asociación	Número de asociaciones activas	Inversión anual
Colaboraciones de investigación académica	7	$850,000
Asociaciones de investigación farmacéutica	4	$1,200,000

Actualizaciones y mejoras de software en curso

POAI mantiene una rigurosa estrategia de mejora de software para sus plataformas de oncología.

• Actualizaciones de plataforma trimestrales
• Refinamiento de algoritmo AI
• Integración de comentarios de los usuarios

Desarrollo de soluciones personalizadas

La oncología predictiva proporciona soluciones personalizadas para investigaciones específicas y requisitos clínicos.

Categoría de soluciones	Nivel de personalización	Tiempo de desarrollo promedio
Modelado de oncología de precisión	Alto	3-6 meses
Predicción de respuesta a las drogas	Medio	2-4 meses

Predictive Oncology Inc. (POAI) - Modelo de negocios: canales

Equipo de ventas directas

A partir del cuarto trimestre de 2023, la oncología predictiva mantiene un equipo de ventas especializado centrado en la tecnología de oncología y las soluciones impulsadas por la IA. El equipo consta de 12 representantes de ventas dedicados dirigidos a instituciones de salud y centros de investigación.

Métricas del equipo de ventas	2023 datos
Representantes de ventas totales	12
Duración del ciclo de ventas promedio	6-8 meses
Segmentos del mercado objetivo	Centros de investigación académicos, clínicas de oncología

Conferencias científicas y simposios médicos

POAI participa en eventos clave de la industria para mostrar innovaciones tecnológicas.

• Conferencia ASCO anual
• Reunión de la Asociación Americana de Investigación del Cáncer (AACR)
• Conferencia Mundial de Medicina de Precisión

Plataforma en línea y marketing digital

Los canales digitales incluyen sitios web corporativos y estrategias de marketing digital específicas.

Métricas de canales digitales	2023 rendimiento
Sitio web Visitantes mensuales	8,500
Seguidores de LinkedIn	3,200
Presupuesto de marketing digital	$ 275,000 anualmente

Publicaciones de la revista académica y médica

POAI aprovecha las publicaciones científicas para demostrar la credibilidad tecnológica.

• Publicado 4 artículos revisados ​​por pares en 2023
• Presentado en Journal of Precision Oncology
• Investigación presentada en el cáncer Research Journal

Redes de asociación estratégica

Asociaciones estratégicas clave a partir de 2024:

Tipo de socio	Número de socios
Instituciones de investigación académica	7
Compañías farmacéuticas	3
Empresas de tecnología de salud	5

Predictive Oncology Inc. (POAI) - Modelo de negocios: segmentos de clientes

Centros de investigación de oncología

A partir de 2024, la oncología predictiva sirve aproximadamente 37 centros de investigación de oncología especializada en los Estados Unidos.

Tipo de centro de investigación	Número de centros	Compromiso anual
Centros designados del Instituto Nacional del Cáncer (NCI)	24	$ 3.2 millones en contratos totales
Instituciones de investigación independientes	13	$ 1.7 millones en contratos totales

Compañías farmacéuticas

POAI colabora con 22 compañías farmacéuticas para plataformas de descubrimiento y desarrollo de drogas.

• Los 10 mejores clientes farmacéuticos representan el 78% de los ingresos del segmento farmacéutico
• Valor promedio del contrato: $ 1.4 millones por cliente farmacéutico
• Áreas terapéuticas: oncología, inmunoterapia, medicina de precisión

Proveedores de atención médica

La compañía se involucra con 45 redes de proveedores de atención médica especializadas en tratamiento del cáncer.

Tipo de red de proveedores	Número de redes	Ingresos anuales
Centros de cáncer integrales	18	$ 2.6 millones
Redes de oncología regional	27	$ 1.9 millones

Instituciones médicas académicas

POAI mantiene asociaciones con 29 instituciones médicas académicas para la colaboración de investigación.

• Universidades de investigación médica de primer nivel: 12
• Financiación total de investigación de asociaciones académicas: $ 4.3 millones
• Valor de subvención de investigación promedio: $ 380,000

Empresas de biotecnología

La compañía trabaja con 16 empresas de biotecnología centradas en oncología y medicina de precisión.

Segmento de biotecnología	Número de empresas	Proyectos de colaboración
Empresas de biotecnología de etapa temprana	8	12 proyectos activos
Empresas de biotecnología establecidas	8	18 proyectos activos

Predictive Oncology Inc. (POAI) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, la oncología predictiva reportó gastos de I + D de $ 3.1 millones, lo que representa una inversión significativa en innovación tecnológica e investigación del cáncer.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 3.1 millones	42.5%
2022	$ 2.7 millones	38.3%

Mantenimiento de la infraestructura tecnológica

Los costos de mantenimiento de infraestructura de tecnología anual para oncología predictiva se estiman en $ 750,000, que cubren:

• Servicios de computación en la nube
• Sistemas de ciberseguridad
• Actualizaciones de hardware y software
• Infraestructura de red

Compensación de personal calificado

Los gastos totales de personal para 2023 fueron de $ 4.2 millones, con el siguiente desglose:

Categoría de personal	Costo anual	Número de empleados
Investigar científicos	$ 1.8 millones	22
Ingenieros de software	$ 1.3 millones	15
Personal administrativo	$ 1.1 millones	18

Licencias y desarrollo de software

Los gastos relacionados con el software para 2023 totalizaron $ 920,000, que incluyen:

• Licencias de software empresarial: $ 350,000
• Desarrollo de software personalizado: $ 570,000

Marketing y desarrollo de negocios

Los gastos de marketing y desarrollo comercial para 2023 fueron de $ 680,000, asignados en varios canales:

Canal de marketing	Gastos
Marketing digital	$280,000
Participación de la conferencia y eventos	$220,000
Materiales de ventas y garantías	$180,000

Predictive Oncology Inc. (POAI) - Modelo de negocios: flujos de ingresos

Tasas de licencia de software

A partir del cuarto trimestre de 2023, la oncología predictiva reportó ingresos por licencia de software de $ 372,000.

Suscripciones de plataforma de diagnóstico

Tipo de plataforma	Tasa de suscripción anual	Suscriptores estimados
Plataforma Curia AI	$ 24,500 por año	12 suscriptores institucionales

Investigación de contratos de colaboración

En 2023, la oncología predictiva aseguró $ 1.2 millones En investigación, la colaboración contratos con instituciones de investigación farmacéutica y académica.

Tarifas de servicio de análisis de datos

• Paquete de análisis de datos estándar: $ 5,500 por proyecto
• Modelado de datos de oncología avanzada: $ 18,000 por análisis integral
• Interpretación de datos de investigación personalizados: $ 35,000 por participación

Licencia de propiedad intelectual

Categoría de IP	Ingresos de licencia 2023
Algoritmos de oncología de IA	$647,000
Modelado de cáncer predictivo	$412,000

Predictive Oncology Inc. (POAI) - Canvas Business Model: Value Propositions

You're looking at how Predictive Oncology Inc. (POAI) is positioning its core offerings in late 2025. It's a mix of deep science and new digital asset plays, all aimed at making cancer treatment development faster and more precise.

Accelerating preclinical drug discovery from years to months

The traditional path for drug discovery is a long haul. Predictive Oncology Inc. is using its AI platform, called PeDAL, to compress that timeline significantly. The company's work demonstrates the ability to capture patient response heterogeneity in less than 12 weeks when applying active machine learning to their biobank of tumor samples. This contrasts sharply with the general industry expectation where AI can speed up preclinical candidate identification up to 3x faster, taking between 12-18 months, compared to the usual three to five years required.

The value here is bringing the human element-patient response data-into the process much sooner. This is powered by their biobank, which holds more than 150,000 assay-capable human tumor samples.

Reducing drug development costs through AI-driven drug repurposing

Repurposing existing, often abandoned, drugs is a major cost-saver. Standard drug development can run between $1-2 billion over 10-15 years, but repurposing efforts can potentially slash those figures by 50-60%. Predictive Oncology Inc. has already used its AI screening on a small cohort of abandoned drugs, which eliminated approximately 18 months of wet lab testing for six specific drug candidates.

Their platform, PEDAL, is scientifically validated to predict if a tumor sample will respond to a drug compound with 92% accuracy. This informed selection de-risks the process substantially. Here's a look at the initial drug repurposing hits identified:

Drug Candidate	Targeted Cancer Indication	Performance Note
Afuresertib	Breast Cancer	Demonstrated high proportion of hits
Alisertib	Colon Cancer	Outperformed Oxaliplatin (standard of care)
Entinosta (Entinostat)	Colon Cancer	Outperformed Oxaliplatin (standard of care)

The company reported identifying three compounds for further exploration in colon and breast cancer as of Q1 2025.

Offering personalized cancer treatment prediction with the ChemoFx® assay

The ChemoFx® assay is Predictive Oncology Inc.'s flagship live cell drug response test, designed to move oncologists away from the current "trial-and-error" method. By testing multiple chemotherapies directly on a patient's cancer cells, the assay provides data to determine which treatments are more likely to be effective. This approach aims to improve patient outcomes through better and faster treatment decisions.

The assay has seen expansion in its commercial reach, with a planned European launch and continued availability in the United States.

• Initial focus: Ovarian and other gynecological cancers.
• Goal: Determine which chemotherapies are more likely to be effective.
• Benefit: Eliminates the current "trial-and-error" approach.

Providing high-performance, enterprise-grade AI compute access via Aethir

Predictive Oncology Inc. is building what it calls the world's first Strategic Compute Reserve, powered by Aethir's decentralized GPU network. This is intended to democratize access to AI infrastructure that has historically been limited by high costs and shortages.

The company initiated this strategy following private placements that delivered approximately $343.5 million in total value, broken down into approximately $50.8 million in cash proceeds and $292.7 million in notional ATH contributions. As of November 10, 2025, Predictive Oncology held approximately 5.70 billion ATH, valued at about $152.8 million based on a price of $0.0268 per ATH. Of that holding, 3.7 billion ATH are locked.

The underlying Aethir network supports enterprise-grade compute using leading Nvidia hardware, including the H100, H200, B200, and B300. The network itself spans more than 435,000 GPU containers across over 200 locations in 93 countries.

You're looking at a company that secured $3.1 million in cash as of March 31, 2025, up from $611,822 at the end of 2024, following the sale of its Skyline Medical assets to focus on this core AI/compute strategy.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Relationships

Direct, high-touch consulting and collaboration with pharmaceutical R&D teams is supported by specific, data-driven engagements.

Predictive Oncology Inc. successfully developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, a global leader of innovative and comprehensive laboratory services, in the second quarter of 2025. This involved both a human and a rat model, representing the liver microenvironment for drug metabolism and toxicity evaluation. Also, in March 2025, the company used its active machine learning platform in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute to develop predictive models derived from 21 unique compounds. The AI platform, PEDAL, claims to predict medicine efficacy on tumor samples with 92% accuracy. The company also reported that after measuring 7% of possible wet lab experiments, its predictive ML model covered 73% of all experiments, virtually eliminating up to two years of laboratory testing in certain scenarios.

Strategic, long-term partnerships for co-development and licensing are a key focus area for funding growth initiatives.

Partner/Collaborator	Date Announced/Reported	Nature of Relationship/Financial Context
Yorkville Advisors Global, LP	July 2025	Entered a Standby Equity Purchase Agreement (SEPA) for up to $10 million in funding to progress drug discovery and business development opportunities with biopharmaceutical companies.
Every Cure	September 2025	Strategic collaboration to pursue drug repurposing, using artificial intelligence to identify new uses for existing drugs.
Tecan Group Ltd.	Q1 2025	Partnered to expand high-throughput drug screening to include human tumor spheroids using automated imaging and 3D analysis.
Labcorp	Q2 2025	Successfully developed two distinct and unique 3D liver toxicity models exclusively for them.

The company is actively pursuing business development opportunities with leading biopharmaceutical firms to leverage its AI capabilities. The $10 million SEPA with Yorkville Advisors is explicitly intended to enable progress on these initiatives.

Automated service delivery for AI compute power via the Aethir network is now integrated into the business structure through a digital asset strategy.

Predictive Oncology Inc. expanded its business to include active digital asset management focused on ATH, the native utility token of the Aethir network, as of December 2025. This strategy was supported by two private placements that resulted in aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million. As of November 10, 2025, the company held approximately 5.70 billion ATH, which had a market value of approximately $152.8 million, based on a price of $0.0268 per ATH. This is intended to allow Predictive Oncology to function as an operator on the Aethir ecosystem to satisfy enterprise demand for compute.

Clinical support for oncologists using the ChemoFx® assay is being aggressively expanded.

ChemoFx® is the proprietary live-cell tumor profiling assay that measures chemotherapy responses in vitro using a patient's own cells to provide personalized guidance for treatment selection. This assay was the primary method by which the company acquired more than 150,000 patient tumor samples, which feeds its biobank.

• Preparing for aggressive market expansion in the U.S. and de novo Launch in Europe as of Q2/Q3 2025.
• Initial focus for the treatment selection marker and tumor profiling assay is on ovarian and other gynecological cancers.
• The assay helps oncologists determine effective chemotherapies, eliminating the current "trial-and-error" approach.

The company reported total revenue of $110,310 for the first quarter ended March 31, 2025. The decrease in revenue for Q2 2025 to $2,682 was primarily due to decreased sales of tumor-specific 3D models and 3D kits.

Finance: review the cash burn rate against the $10 million SEPA funding availability by end of Q4 2025.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Channels

You're looking at how Predictive Oncology Inc. (POAI) gets its value propositions-from AI drug discovery to its new digital asset strategy-into the hands of customers and stakeholders as of late 2025. The channels have definitely shifted, moving beyond just lab services to a heavy focus on digital infrastructure partnerships.

Direct sales and business development teams targeting biopharma executives

This channel remains critical for the core oncology business, specifically for driving adoption of the ChemoFx® assay and securing data licensing or drug repurposing collaborations. While we don't have a headcount for the direct sales force, we can look at the associated spending to gauge the effort behind this push. Sales and marketing expenses for the second quarter of 2025 hit $268,959, up from $134,186 in the comparable period in 2024, largely due to increased fees for digital marketing consultants as they push for market expansion. Also, general and administrative expenses, which cover overhead for these efforts, were $2.6 million in the third quarter of 2025. The company is actively exploring strategic partnerships with biopharmaceutical companies to advance its drug repurposing candidates, such as the three identified compounds: Afuresertib, Alisertib, and Entinosta. Honestly, this channel is where the traditional science meets the market.

Digital asset platforms and the Aethir network for compute services

This is the newer, high-profile channel, positioning Predictive Oncology Inc. as an operator on the Aethir ecosystem to monetize its Strategic Compute Reserve. This strategy was funded by massive capital raises in late 2025. The network itself is substantial, spanning more than 435,000 GPU containers across 200+ locations in 93 countries, supporting hardware like Nvidia H100, H200, B200, and B300. The channel's success is tied to the value of the assets acquired to operate within it. Here's the quick math on the holdings as of November 10, 2025:

Asset Metric	Value
Total ATH Tokens Held	5.70 billion
Market Value of ATH (as of Nov 10, 2025)	$152.8 million
ATH Price Used for Valuation	$0.0268 per ATH
Locked/Restricted ATH	3.7 billion
Unlocked ATH	2.0 billion

The plan is to drive a high single-digit yield on these digital assets by FY'26 through staking and GPU leasing, which is how they intend to generate booked revenue from this channel.

Clinical laboratory network for ChemoFx® assay distribution

The ChemoFx® assay distribution channel is focused on clinical utility, helping oncologists select better chemotherapy treatments. The company is aggressively advancing its market expansion for this flagship live cell drug response assay. They anticipated a de novo launch in Europe in the fourth quarter of 2025, complementing its ongoing U.S. availability. This assay is deeply integrated with their AI platform, as the data generated feeds back into their models. You should know that the foundation of this capability rests on their extensive biobank, which contains over 150,000 tumor samples across 137 types of cancer. The assay initially targets ovarian and other gynecological cancers, with plans to include other major tumor types over time.

Investor relations for capital raising and strategic financing

This channel is about securing the necessary capital to fund operations and execute the new digital asset strategy. The most significant recent event was the closing of two private investment in public equity (PIPE) transactions on October 7, 2025. This was a major influx of funding to support the Aethir (ATH) treasury strategy. The total aggregate raised was approximately $343.5 million. What this estimate hides is the split between cash and crypto value, which is important for understanding the immediate liquidity versus the strategic asset base:

• Cash Gross Proceeds: Approximately $50.8 million.
• In-Kind ATH Contributions (Notional Value): Approximately $292.7 million.
• In-Kind ATH Contributions (Discounted Value): Roughly $173.3 million.

This financing was crucial; following the closing, Predictive Oncology Inc. stated its stockholders' equity exceeded $2.5 million, allowing them to regain compliance with Nasdaq Listing Rule 5550(b)(1) as of December 1, 2025. For context on the operational burn this financing is meant to cover, net cash used in operating activities for the first nine months of 2025 was $5.9 million.

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Segments

Large pharmaceutical and biotech companies seeking to replenish pipelines.

Predictive Oncology Inc. is exploring partnership opportunities with major biopharmaceutical firms to leverage its artificial intelligence and machine learning platform for drug repurposing. The company has already developed a registry for repurposing abandoned drugs, identifying 3 compounds for further exploration in colon and breast cancer indications.

Oncologists and clinicians focused on gynecological and ovarian cancers.

The ChemoFx®, validated flagship live cell drug response assay, is being prepared for aggressive market expansion in the U.S. and a de novo launch in Europe. This assay initially focuses on ovarian and other gynecological cancers to help determine effective chemotherapies, eliminating the current trial-and-error approach.

Global enterprises requiring decentralized, high-demand GPU compute power.

Predictive Oncology Inc. initiated a digital asset treasury strategy focused on ATH, the native utility token of the Aethir network, to function as an operator on the Aethir ecosystem. This allows the company to satisfy enterprise demand for compute through its Strategic Compute Reserve. The company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million pursuant to private placements supporting this strategy. As of November 10, 2025, the Company held approximately 5.70 billion ATH, with a market value of approximately $152.8 million. The PEDAL platform, which utilizes these capabilities, achieves 92% tumor response prediction accuracy.

Non-profit organizations focused on drug repurposing, like Every Cure.

The company's AI/ML platform is instrumental in identifying new uses for abandoned or discontinued drugs for novel cancer treatments. Predictive Oncology Inc. has developed a portfolio of promising candidates that may potentially be repurposed for additional or alternative indications.

Key metrics related to Predictive Oncology Inc. (POAI) customer-facing offerings as of late 2025:

Customer Segment Focus	Key Offering/Metric	Latest 2025 Figure
Drug Repurposing/Pharma	Identified repurposed drug candidates (Colon/Breast)	3 compounds
Oncologists/Clinicians	ChemoFx® initial focus	Ovarian and gynecological cancers
Compute/Enterprises	PEDAL platform prediction accuracy	92%
Compute/Enterprises	ATH Token Holdings (Market Value)	$152.8 million (as of Nov 10, 2025)

The company's strategic focus areas for customer engagement include:

• Leveraging AI/ML for drug discovery and development.
• Expanding ChemoFx® availability in the U.S. and Europe.
• Monetizing AI infrastructure through enterprise deployments.
• Developing systems to utilize ATH tokens for revenue generation.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Predictive Oncology Inc.'s expenses as of late 2025. The cost structure is clearly bifurcated between traditional operational expenses and the significant impact of the new digital asset strategy.

The General and Administrative expenses were high for the third quarter of 2025, totaling $2.6 million for the three months ended September 30, 2025. This compares to $1.5 million in the same period in 2024. This increase was driven by specific cost components.

The core scientific and development spending, categorized as Operations, research, and development expense, was $528,557 for the three months ended September 30, 2025. This was largely flat compared to $535,236 in the comparable period in 2024.

The most significant financial event impacting the income statement for the quarter was the non-cash charge related to the digital asset treasury strategy. Predictive Oncology Inc. recorded a loss on derivative instruments of $74.4 million in Q3 2025, which is directly tied to the valuation of the ATH token holdings.

Here's a quick look at the key reported operating expenses for Q3 2025:

Expense Category	Amount for Three Months Ended September 30, 2025
General and Administrative Expenses	$2.6 million
Operations, Research and Development Expense	$528,557
Sales and Marketing Expenses	$133,494
Revenue (for comparison)	$3,618

The increase in General and Administrative expenses was specifically attributed to higher spending in two areas:

• Increased legal fees.
• Increased stock-based compensation expense due to restricted stock units granted to employees, directors, and consultants.

Maintaining the core drug discovery infrastructure represents a fixed cost base. This includes the physical assets supporting the AI platform:

• Costs associated with maintaining the biobank, which holds more than 150,000 assay-capable heterogenous human tumor samples.
• Costs for the wholly owned CLIA lab facility.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Revenue Streams

You're looking at the top line for Predictive Oncology Inc. (POAI) as of late 2025, and honestly, the picture is dominated by the strategic pivot. While the foundational streams-fees from AI-driven drug discovery services and platform licensing-are still part of the overall business, the current reported revenue is quite minimal, suggesting these services haven't scaled to drive significant top-line growth yet. The ChemoFx® drug response assay, which is key to their biobank, also represents a potential revenue source, but specific figures aren't broken out in the latest reports.

The major focus for future revenue generation is clearly the new digital asset strategy. Predictive Oncology Inc. is building out its Strategic Compute Reserve, intending to monetize this via staking and GPU rentals on the Aethir network. They are targeting a high single-digit yield on their ATH tokens by 2026, so this is definitely a forward-looking stream, not one contributing materially to the current numbers.

Here's the quick math on the realized revenue from continuing operations through the third quarter of 2025. The numbers show the current state before the compute monetization is expected to kick in.

Revenue Metric	Amount (USD)
Total Revenue (Nine Months Ended September 30, 2025)	$116,610
Q3 2025 Operating Revenue	$3,618

To be fair, that Q3 2025 operating revenue of $3,618 was described as minimal and nearly flat year-over-year. The total revenue for the nine months ended September 30, 2025, at $116,610, is up from $76,020 in the prior year period, which is a positive trend, even if the absolute dollar amounts are small relative to the company's asset base.

The streams that underpin the current, albeit small, revenue include:

• AI-driven drug discovery service fees.
• Platform licensing revenue.
• Sales related to the ChemoFx® assay.

Finance: draft 13-week cash view by Friday.